Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Additional Paid-In Capital

Last Annual Value

995.82M

3-Year CAGR

19%

5-Year CAGR

28%

10-Year CAGR

133%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Additional Paid-In Capital

CGEM · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
995.82M
15.0%11.2%N/A 
483.30M
2.4%1.5%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
375.50M
197.7%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
443.60M
2.2%-16.5%N/A
1.73B
26.3%15.8%13.4%
0.00
N/AN/AN/A
804.39M
8.4%11.3%N/A
791.75M
2.8%2.3%6.2%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21